Back to Journals » OncoTargets and Therapy » Volume 7

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer

Authors Della Pepa C, Banerjee S

Received 31 December 2013

Accepted for publication 6 April 2014

Published 19 June 2014 Volume 2014:7 Pages 1025—1032

DOI https://doi.org/10.2147/OTT.S40527

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 5


Chiara Della Pepa, Susana Banerjee

Gynecology Unit, The Royal Marsden NHS Foundation Trust, London, UK

Abstract: Targeting angiogenesis is proving to be a successful approach in the management of ovarian cancer. The vascular endothelial growth factor inhibitor, bevacizumab, is the first angiogenesis inhibitor to have shown a significant progression-free survival advantage in the Phase III setting. There is now evidence supporting the use of bevacizumab in combination with chemotherapy for first-line and relapsed (platinum-sensitive and resistant) ovarian cancer. In this review, we summarize the positive Phase III trial (OCEANS [Ovarian Cancer Study Comparing Efficacy and Safety of Chemotherapy and Anti-Angiogenic Therapy in Platinum-Sensitive Recurrent Disease]) that led to European Medicines Agency approval of bevacizumab in platinum-sensitive first relapse and discuss the best use of the drug in this disease.

Keywords: antiangiogenic, recurrent, ovarian


Corrigendum for this paper has been published

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]